journal
https://read.qxmd.com/read/35694977/extranodal-classical-hodgkin-lymphoma-involving-the-spinal-cord-case-report-and-review-of-the-literature
#21
JOURNAL ARTICLE
Katell Le Dû, Nicolas Alarion, Hassan Rabi, Olivier Casasnovas, Philippine Robert, Amandine Durand, Bénédicte Burlet, Claire Tabouret-Viaud, Selim Ramla, Laurent Martin, Cédric Rossi
Primary CNS involvement is very rare in Hodgkin lymphoma. Here we present two cases of spinal cord dissemination. Two women of 40 and 65 years of age presented symptoms of spinal cord injury; imaging showed an intramedullary mass in T10 and T2, respectively, without vertebral involvement and upper diaphragmatic lymph nodes. Lymph-node biopsy confirmed the diagnosis of classical Hodgkin lymphoma in both patients. The first patient received four cycles of chemotherapy (escalated BEACOPP and ABVD) with intrathecal therapy, and the second four cycles of doxorubicin, vinblastine, dacarbazine (AVD) and local irradiation after surgery decompression...
June 13, 2022: CNS Oncology
https://read.qxmd.com/read/35603818/radiotherapy-drug-combinations-in-the-treatment-of-glioblastoma-a-brief-review
#22
REVIEW
Patrick G McAleavey, Gerard M Walls, Anthony J Chalmers
Glioblastoma (GBM) accounts for over 50% of gliomas and carries the worst prognosis of all solid tumors. Owing to the limited local control afforded by surgery alone, efficacious adjuvant treatments such as radiotherapy (RT) and chemotherapy are fundamental in achieving durable disease control. The best clinical outcomes are achieved with tri-modality treatment consisting of surgery, RT and systemic therapy. While RT-chemotherapy combination regimens are well established in oncology, this approach was largely unsuccessful in GBM until the introduction of temozolomide...
June 1, 2022: CNS Oncology
https://read.qxmd.com/read/35583041/daily-functioning-in-glioma-survivors-associations-with-cognitive-function-psychological-factors-and-quality-of-life
#23
JOURNAL ARTICLE
Kathleen Van Dyk, Lucy Wall, Brandon F Heimberg, Justin Choi, Catalina Raymond, Chencai Wang, Albert Lai, Timothy F Cloughesy, Benjamin M Ellingson, Phioanh Nghiemphu
Aim: Understanding and supporting quality of life (QoL) and daily functioning in glioma patients is a clinical imperative. In this study, we examined the relationship between cognition, psychological factors, measures of health-related QoL and functioning in glioma survivors. Materials & methods: We examined neuropsychological, self-reported cognition, mood and QoL correlates of work and non-work-related daily functioning in 23 glioma survivors, and carried out linear models of the best predictors. Results & conclusion: A total of 13/23 participants were working at the time of enrollment...
June 1, 2022: CNS Oncology
https://read.qxmd.com/read/35373582/systemic-inflammatory-biomarkers-in-primary-central-nervous-system-lymphoma-versus-high-grade-glioma-exploratory-comparative-and-correlative-analysis
#24
JOURNAL ARTICLE
Tejpal Gupta, Prashant Nayak, Yamini Baviskar, Meetakshi Gupta, Aliasgar Moiyadi, Sridhar Epari, Amit Janu, Nilendu Purandare, Venkatesh Rangarajan, Bhausaheb Bagal, Abhishek Chatterjee, Goda Jayant Sastri
Aim: To assess systemic inflammatory biomarkers in non invasive differential diagnosis of primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG). Materials & methods: Patients with similar morphology (PCNSL or HGG) on conventional neuro-imaging were included. Systemic inflammatory indices were calculated from pretreatment complete blood counts and liver function tests and compared against histopathology as reference standard. Results: Mean values of absolute lymphocyte count and prognostic nutritional index were significantly different between PCNSL (n = 42) versus HGG (n = 16)...
June 1, 2022: CNS Oncology
https://read.qxmd.com/read/35575067/a-first-in-human-phase-i-trial-of-the-oral-p-stat3-inhibitor-wp1066-in-patients-with-recurrent-malignant-glioma
#25
JOURNAL ARTICLE
John de Groot, Martina Ott, Jun Wei, Cynthia Kassab, Dexing Fang, Hinda Najem, Barbara O'Brien, Shiao-Pei Weathers, Carlos Kamiya Matsouka, Nazanin K Majd, Rebecca A Harrison, Gregory N Fuller, Jason T Huse, James P Long, Raymond Sawaya, Ganesh Rao, Tobey J MacDonald, Waldemar Priebe, Michael DeCuypere, Amy B Heimberger
Aim: To ascertain the maximum tolerated dose (MTD)/maximum feasible dose (MFD) of WP1066 and p-STAT3 target engagement within recurrent glioblastoma (GBM) patients. Patients & methods: In a first-in-human open-label, single-center, single-arm 3 + 3 design Phase I clinical trial, eight patients were treated with WP1066 until disease progression or unacceptable toxicities. Results: In the absence of significant toxicity, the MFD was identified to be 8 mg/kg. The most common adverse event was grade 1 nausea and diarrhea in 50% of patients...
May 16, 2022: CNS Oncology
https://read.qxmd.com/read/35535978/large-mirror-brain-metastases-from-primary-undifferentiated-sarcoma-of-the-breast-case-report-and-review-of-the-literature
#26
JOURNAL ARTICLE
Nuno Cubas Farinha, Wilson Teixeira, Diogo Roque, Sergio Livraghi
Primary breast sarcomas are rare high-grade tumors with a reported incidence of <1% of breast malignancies. Its dissemination to the CNS is exceptional and only one is found in the literature. The authors described the case of a 22-year-old female with history of a breast undifferentiated sarcoma that present with two large bilateral retrolenticular brain metastases. Both lesions were excised in the same procedure and she underwent adjuvant therapy. She died 24 months after surgery. Despite being aggressive lesions, aggressive treatment of primary breast sarcomas including brain metastases excision, should be considered in order to improve overall survival...
May 10, 2022: CNS Oncology
https://read.qxmd.com/read/35382555/insight-about-the-characteristics-and-surgical-resectability-of-adult-pilocytic-astrocytoma-tertiary-center-experience
#27
JOURNAL ARTICLE
Baha'eddin A Muhsen, Abdelmajid I Aljariri, Maher Elayyan, Hawazen Hirbawi, Mahmoud A Masri
Aim: Adult pilocytic astrocytoma is a rare tumor. We aim to contribute to understanding its clinical course and prognosis. Patients & methods: We searched our database for patients older than 18 years with pathology-proven pilocytic astrocytoma. Patients' clinical data were analyzed. Results: Fifteen patients were identified. The median age at diagnosis was 25 years (range: 18-56). Tumors were supratentorial in 47%. Gross-total and near-total resections were achieved in 40%, and sub-total resection in 47%...
April 6, 2022: CNS Oncology
https://read.qxmd.com/read/35043686/prolonged-response-of-recurrent-idh-wild-type-glioblastoma-to-laser-interstitial-thermal-therapy-with-pembrolizumab
#28
JOURNAL ARTICLE
Helen Hwang, Jiayi Huang, Karam Khaddour, Omar H Butt, George Ansstas, Jie Chen, Ruth Gn Katumba, Albert H Kim, Eric C Leuthardt, Jian L Campian
Despite the improved understanding of the molecular and genetic heterogeneity of glioblastoma, there is still an unmet need for better therapeutics, as treatment approaches have remained unchanged in recent years. Research into the role of the immune microenvironment has generated enthusiasm for testing immunotherapy (specifically, immune checkpoint inhibitors). However, to date, trials of immunotherapy in glioblastoma have not demonstrated a survival advantage. Combination approaches aimed at optimally inducing response to immune checkpoint inhibitors with radiotherapy are currently being investigated...
March 1, 2022: CNS Oncology
https://read.qxmd.com/read/35142534/challenges-of-imaging-interpretation-to-predict-oligodendroglioma-grade-a-report-from-the-neuro-oncology-branch
#29
JOURNAL ARTICLE
Orwa Aboud, Ritu Shah, Elizabeth Vera, Eric Burton, Brett Theeler, Jing Wu, Lisa Boris, Martha Quezado, Jennifer Reyes, Kathleen Wall, Mark R Gilbert, Terri S Armstrong, Marta Penas-Prado
Background: To illustrate challenges of imaging interpretation in patients with oligodendroglioma seen at a referral center and evaluate interrater reliability. Methods: Two neuro-oncologists reviewed diagnostic preradiation MRIs of oligodendroglioma patients; interrater reliability was calculated with the kappa coefficient (k). A neuroradiologist measured presurgical apparent diffusion coefficient (ADC), if available. Results: Extensive enhancement was noted in four of 58 patients, k = 0.7; necrosis in seven of 58, k = 0...
February 10, 2022: CNS Oncology
https://read.qxmd.com/read/34806399/a-pragmatic-diagnostic-approach-to-primary-intracranial-germ-cell-tumors-and-their-treatment-outcomes
#30
JOURNAL ARTICLE
Jeyaanth Venkatasai, Rajesh Balakrishnan, Balakrishnan Rajkrishna, Patricia Sebastain, Rikki Rorima John, Harshad Arvind Vanjare, Krishna Prabhu, Bijesh Nair, Leni Grace Mathew, Selvamani Backianathan
Background: Primary intracranial germ cell tumors (ICGCT) are often diagnosed with tumor markers and imaging, which may avoid the need for a biopsy. An intracranial germ cell tumor with mild elevation of markers is seldom stratified as a distinct entity. Methods: Fifty-nine patients were stratified into three groups: pure germinoma (PG), secreting germinoma (SG) and non-germinomatous germ cell tumors (NGGCTs). Results: At 5 years, progression-free survival and overall survival of the three groups (PG vs SG vs NGGCT) were 91% versus 81% versus 59%, and 100% versus 82% versus 68%, respectively...
November 22, 2021: CNS Oncology
https://read.qxmd.com/read/34636248/multi-joint-steroid-induced-avascular-necrosis-in-a-malignant-brain-tumor-patient
#31
JOURNAL ARTICLE
Jessica M Lewis-Gonzalez, Mallika P Patel, Katherine B Peters
Avascular necrosis (AVN) is a rare but serious adverse event associated with the use of corticosteroids for long durations or at high doses. This case report describes a 47-year-old female patient with low-grade astrocytoma who was initiated on low-dose dexamethasone for symptom management. The patient developed joint pain 1 year after steroid exposure, then was found to have AVN of the hip followed by multiple other joints. This case report highlights the extent to which AVN can occur in patients with brain tumors following a short course of low-dose corticosteroids...
October 12, 2021: CNS Oncology
https://read.qxmd.com/read/34545753/primary-brain-tumor-patients-admitted-to-a-us-intensive-care-unit-a-descriptive-analysis
#32
JOURNAL ARTICLE
Jennifer H Kang, Christa B Swisher, Evan D Buckley, James E Herndon, Eric S Lipp, John P Kirkpatrick, Annick Desjardins, Henry S Friedman, Margaret O Johnson, Dina M Randazzo, David M Ashley, Katherine B Peters
Purpose: To describe our population of primary brain tumor (PBT) patients, a subgroup of cancer patients whose intensive care unit (ICU) outcomes are understudied. Methods: Retrospective analysis of PBT patients admitted to an ICU between 2013 to 2018 for an unplanned need. Using descriptive analyses, we characterized our population and their outcomes. Results: Fifty-nine PBT patients were analyzed. ICU mortality was 19% (11/59). The most common indication for admission was seizures (n = 16, 27%). Conclusion: Our ICU mortality of PBT patients was comparable to other solid tumor patients and the general ICU population and better than patients with hematological malignancies...
September 21, 2021: CNS Oncology
https://read.qxmd.com/read/34486380/identifying-the-optimal-cutoff-point-for-mgmt-promoter-methylation-status-in-glioblastoma
#33
JOURNAL ARTICLE
Ngan Nguyen, Jordan Redfield, Matthew Ballo, Madison Michael, Jeffrey Sorenson, Daniel Dibaba, Jim Wan, Glenda Delgado Ramos, Manjari Pandey
Aim: To define the optimal cutoff point for determining methylation status of O6-methylguanine-DNA methyltransferase (MGMT) by pyrosequencing in glioblastoma. Patients & methods:  A retrospective study of 109 glioblastoma patients was performed to determine the optimal cutoff point for MGMT methylation status. Results: Receiver operating characteristic (ROC) analysis revealed 21% as the optimal cutoff (sensitivity: 68%; specificity: 59%) for MGMT methylation corresponding with the highest likelihood ratio of 1...
September 1, 2021: CNS Oncology
https://read.qxmd.com/read/34469205/histone-mutant-glioma-presenting-as-diffuse-leptomeningeal-disease
#34
JOURNAL ARTICLE
Tanvi Nadkarni, Kimberly Hamilton, Faraze Niazi, Melanie Ward, Uchenna Okakpu, Rudolph J Castellani, Ion Prisneac, Ugur Sener
Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Histone H3 mutations have been identified in pediatric and adult gliomas, with H3K27M mutations typically associated with a posterior fossa midline tumor location and poor prognosis. Leptomeningeal disease is a known complication of histone-mutant glioma, but uncommon at the time of initial diagnosis. We describe a case of glioblastoma with H3K27M mutation that initially presented with progressive vision loss due to diffuse leptomeningeal disease in the absence of a mass lesion other than a small cerebellar area of enhancement and with cerebrospinal fluid cytology negative for malignant cells on two occasions, highlighting the importance of including primary CNS malignancies in the differential of diffuse radiographic leptomeningeal enhancement...
September 1, 2021: CNS Oncology
https://read.qxmd.com/read/34378977/treatment-patterns-and-outcomes-for-patients-with-newly-diagnosed-glioblastoma-multiforme-a-retrospective-cohort-study
#35
JOURNAL ARTICLE
Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert
Aim: Investigate real-world outcomes and healthcare utilization of patients with glioblastoma multiforme (GBM) related to O6 -methylguanine DNA methyltransferase (MGMT) promoter testing and methylation. Patients & methods: US Oncology Network data were analyzed for patients receiving first-line (1L) treatment for GBM. Results: Most patients received 1L radiation with temozolomide. Unadjusted median overall survival (OS) was higher in tested versus untested (median:18.1 vs 11.8 months) and in methylated versus unmethylated (median: 25...
August 11, 2021: CNS Oncology
https://read.qxmd.com/read/34015961/next-generation-sequencing-reveals-novel-mutations-in-a-collision-tumor-of-glioblastoma-and-meningioma
#36
JOURNAL ARTICLE
Kelly Chamberlin, Gregory Chamberlin, Katherine Saunders, Simon Khagi
Primary intracranial collision tumors are rare in patients without predisposing factors. We report such a case in a 42-year-old female who presented with headaches and altered mental status. Imaging revealed a single heterogeneous, rim-enhancing lesion in the left parieto-occipital periventricular region, involving the corpus callosum. Stereotactic biopsy demonstrated glioblastoma. Subsequent tumor resection showed histologic evidence of glioblastoma and meningioma. Next-generation sequencing was performed on both tumor components...
June 1, 2021: CNS Oncology
https://read.qxmd.com/read/34015955/meningioma-not-always-a-benign-tumor-a-review-of-advances-in-the-treatment-of-meningiomas
#37
REVIEW
Ilaria Maggio, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Lidia Gatto, Raffaele Lodi, Alba A Brandes
Meningiomas are the most common primary intracranial tumors. The majority of meningiomas are benign, but they can present different grades of dedifferentiation from grade I to grade III (anaplastic/malignant) that are associated with different outcomes. Radiological surveillance is a valid option for low-grade asymptomatic meningiomas. In other cases, the treatment is usually surgical, aimed at achieving a complete resection. The use of adjuvant radiotherapy is the gold standard for grade III, is debated for grade II and is not generally indicated for radically resected grade I meningiomas...
June 1, 2021: CNS Oncology
https://read.qxmd.com/read/34006134/stem-cells-for-the-treatment-of-glioblastoma-a-20-year-perspective
#38
JOURNAL ARTICLE
Anda-Alexandra Calinescu, McKenzie C Kauss, Zain Sultan, Wajd N Al-Holou, Sue K O'Shea
Glioblastoma, the deadliest form of primary brain tumor, remains a disease without cure. Treatment resistance is in large part attributed to limitations in the delivery and distribution of therapeutic agents. Over the last 20 years, numerous preclinical studies have demonstrated the feasibility and efficacy of stem cells as antiglioma agents, leading to the development of trials to test these therapies in the clinic. In this review we present and analyze these studies, discuss mechanisms underlying their beneficial effect and highlight experimental progress, limitations and the emergence of promising new therapeutic avenues...
May 19, 2021: CNS Oncology
https://read.qxmd.com/read/33908265/diffuse-midline-glioma-with-h3-k27m-mutation-in-an-83-year-old-woman
#39
JOURNAL ARTICLE
Justin Thomas Low, Shih-Hsiu Wang, Katherine B Peters
Diffuse midline gliomas harboring histone H3 K27M mutations are most commonly found in the brainstem of children. This mutation confers a WHO grade IV designation and is associated with a particularly poor prognosis. Although traditionally considered to be a disease of children and young adults, a number of recent reports have described H3 K27M mutations in older adults with diffuse midline gliomas. Here, we present the unusual case of a diffuse midline glioma in the pons and cerebellum of an 83-year-old woman and review the evolving clinical literature on this entity in adults...
April 28, 2021: CNS Oncology
https://read.qxmd.com/read/33448230/adult-pilocytic-astrocytoma-in-the-molecular-era-a-comprehensive-review
#40
JOURNAL ARTICLE
Timothy A Gregory, Lyndon B Chumbley, John W Henson, Brett J Theeler
Adult pilocytic astrocytoma (PA) is less prevalent than pediatric PA and is associated with a worse prognosis. In a literature review, we found that 88.3% of the molecular alterations in adult PA are associated with MAPK pathway dysregulation. The most common alterations are fusions of BRAF . Understanding of the mechanisms underlying this pathway has evolved substantially, heralding advancements in specific targeted therapy. Here, we review clinical and molecular features of adult PA, characteristics predicting aggressive behavior and approaches to standard and investigational therapies...
March 1, 2021: CNS Oncology
journal
journal
47537
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.